NCT06613633View on ClinicalTrials.gov

Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

CompletedOBSERVATIONAL

Enrollment

4,000

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

August 1, 2024

Study Completion Date

September 20, 2024

Conditions

Third-generation TKINSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

DRUG

third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)

Patients with advanced EGFR-mutated NSCLC who met the inclusion criteria and received third-generation EGFR-TKI (monotherapy or combined with brain radiotherapy)

Trial Locations (3)

200050

Shanghai Cancer Center, Shanghai

430030

Wuhan Tongji Hospital, Wuhan

Unknown

Shanghai Chest Hospital, Shanghai

All Listed Sponsors

collaborator

Shanghai Chest Hospital

OTHER

collaborator

Wuhan TongJi Hospital

OTHER

lead

Fudan University

OTHER

NCT06613633 - Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC | Biotech Hunter | Biotech Hunter